The Swedish real-world study tested the PrecivityAD2 blood test in routine care for memory concerns. For people with MCI, early but noticeable thinking changes, local primary care reached near-specialist accuracy after seeing the result. Researchers led by Lund neurologist Sebastian Palmqvist presented the work at AAIC 2026 in London on July 14, 2026. The Alzheimer's Association says the interim analysis included 1,310 people with mild cognitive impairment or dementia, with 383 seen in primary care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the clinics actually do?
- How much did accuracy improve?
- How did results change care?
- What should you discuss at your visit?
What did the clinics actually do?
The Alzheimer's Association reports the study enrolled patients during normal appointments in primary and specialty care Alzheimer's Association release. It included 165 physicians across primary care and dementia specialty clinics. Of the group, 927 patients were evaluated by dementia specialists.
The doctors first gave a diagnosis from history, exams, and standard workup. Clinical Lab Products reports the PrecivityAD2 result measures amyloid-beta and phosphorylated tau linked to Alzheimer pathology. Doctors then reviewed that result to update the diagnosis.
How much did accuracy improve?
Primary-care accuracy rose from about 65% before blood results to about 93% after, according to Clinical Lab Products Clinical Lab Products report. Specialists rose from about 74% to about 89% in the same comparison. The gain was largest where starting accuracy was lowest.
When the same primary-care patients were reviewed by both groups, each reached around 90% accuracy after seeing blood results. The Alzheimer's Association reports this direct head-to-head comparison. In practice, a local visit plus blood work matched specialist judgment.
How did results change care?
The Alzheimer's Association reports physicians changed the diagnosis in about one-third of patients after disclosure. They changed planned care or further testing in more than half. The greatest value was ruling out Alzheimer disease in primary care.
Ruling out means symptoms likely come from another cause, such as sleep, mood, medication, or vascular issues. Ruling in points toward Alzheimer pathology and focuses next steps. Either answer reduces long uncertainty for families.
What should you discuss at your visit?
For MCI, the practical gain is local clarity. The Alzheimer's Association overview suggests a primary-care blood test can give near-specialist accuracy without long referral waits.
That earlier answer can guide next steps sooner. These were interim conference results that still need peer-reviewed publication and validation. The FDA notes in its clearance notice that blood tests aid diagnosis in adults with symptoms, not as screening alone FDA clearance notice.
- Bring dated examples of memory changes, daily effects, and all medications.
- Ask how the result would change diagnosis, referrals, or added testing.
- Set a follow-up plan for either result, including other causes if Alzheimer is ruled out.
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: A Source-Checked Briefing for People With Mild Cognitive Impairment
- NIA’s 2026 Food Insecurity and Cognitive Health Workshop: Research Participation Questions for People With Mild Cognitive Impairment
- Healthy Diets in the 2026 WHO Dementia Guideline: How the Advice Compares With Common Online Claims for People With Mild Cognitive Impairment
